Denosumab and Zoledronic Acid Differently Affect Circulating Immune Subsets: A Possible Role in the Onset of MRONJ

This work investigated whether the anti-resorptive drugs (ARDs) zoledronic acid (Zol) and denosumab (Dmab) affect differently the levels of circulating immune cell subsets, possibly predicting the risk of developing medication-related ONJ (MRONJ) during the first 18 months of treatment. Blood sample...

Descripción completa

Detalles Bibliográficos
Autores principales: Roato, Ilaria, Pavone, Lorenzo, Pedraza, Riccardo, Bosso, Ilaria, Baima, Giacomo, Erovigni, Francesco, Mussano, Federico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605172/
https://www.ncbi.nlm.nih.gov/pubmed/37887274
http://dx.doi.org/10.3390/cells12202430

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605172/
https://www.ncbi.nlm.nih.gov/pubmed/37887274
http://dx.doi.org/10.3390/cells12202430

Ejemplares similares